Cornel Iridoid Glycoside Regulates Modification of Tau and Alleviates Synaptic Abnormalities in Aged P301S Mice

Abstract

Alzheimer’s disease (AD), also defined as a tauopathology, is a common neurodegenerative disease. Hyper-phosphorylation, cleavage or truncation, and aggregation of tau contribute to AD. Thus, targeting the post-translational modifications on tau may be a therapeutic strategy to treat AD. This study understood how cornel iridoid glycoside (CIG) affects tau post-translational modifications and synaptic abnormalities. The 10-month old P301S tau transgenic mice were given CIG at 100 and 200 mg/kg every day orally for 1 month. Hyperphosphorylated and truncated tau, synapse-associated proteins and glutamatergic receptors were all detected using Western blotting. The interactions between Morroniside (MOR) or Loganin (LOG) and tau were detected using Autodock and Surface Plasmon Resonance (SPR). The effects of CIG on the aggregation of tau were investigated using a cell-free system. CIG attenuated tau hyperphosphorylation at Thr205, Ser212, Ser262, Thr231 and Ser235 (AT180), but had no effect on tau truncation in the brains of 10-month old P301S mice. Binding free energies and interactions revealed that MOR and LOG bound with tau. We also found that CIG upregulated synapse-associated proteins such as PSD-95, syntaxin1A and synaptotagmin. In addition, CIG restored N-methyl-D-aspartic acid receptor and glutamate receptor levels. CIG improves post-translational modification of tau as well as synaptic abnormalities. The data presented here reveal that CIG may be used in the treatment of AD.

Keywords

cornel iridoid glycoside / tau / synaptic abnormality / glutamate receptor / P301S

References

[1] ZhangH, GuoY, MengL, et al.. Rapid Screening and Characterization of Acetylcholinesterase Inhibitors from Yinhuang Oral Liquid Using Ultrafiltration-liquid Chromatography-electrospray Ionization Tandem Mass Spectrometry. Pharmacogn Mag, 2018, 14(54): 248-252

[2] LiuF, GongCX. Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener, 2008, 3: 8

[3] PapanikolopoulouK, SkoulakisEMC. Altered Proteostasis in Neurodegenerative Tauopathies. Adv Exp Med Biol, 2020, 1233: 177-194

[4] JouanneM, RaultS, Voisin-ChiretAS. Tau protein aggregation in Alzheimer’s disease: An attractive target for the development of novel therapeutic agents. Eur J Med Chem, 2017, 139: 153-167

[5] GuhaS, JohnsonGVW, NehrkeK. The Crosstalk Between Pathological Tau Phosphorylation and Mitochondrial Dysfunction as a Key to Understanding and Treating Alzheimer’s Disease. Mol Neurobiol, 2020, 57(12): 5103-5120

[6] HeftiMM, KimS, BellAJ, et al.. Tau Phosphorylation and Aggregation in the Developing Human Brain. J Neuropathol Exp Neurol, 2019, 78(10): 930-938

[7] JadhavS, ZilkaN, NovakM. Protein truncation as a common denominator of human neurodegenerative foldopathies. Mol Neurobiol, 2013, 48(3): 516-532

[8] HungSY, FuWM. Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci, 2017, 24(1): 47

[9] Ferreira-VieiraTH, GuimaraesIM, SilvaFR, et al.. Alzheimer’s disease: Targeting the Cholinergic System. Curr Neuropharmacol, 2016, 14(1): 101-115

[10] BaiCK, WuYM, CaoB, et al.. De novo transcriptome assembly based on RNA-seq and dynamic expression of key enzyme genes in loganin biosynthetic pathway of Cornus officinalis. Tree Genet Genomes, 2018, 14(4): 57

[11] WangX, LiuCH, LiJJ, et al.. Iridoid glycosides from the fruits of Cornus officinalis. J Asian Nat Prod Res, 2018, 20(10): 934-942

[12] MaD, ZhuY, LiY, et al.. Benefcial effects of cornel iridoid glycoside on behavioral impairment and senescence status in SAMP8 mice at different ages. Behav Brain Res, 2016, 312: 20-29

[13] YangC, BaoX, ZhangL, et al.. Cornel iridoid glycoside ameliorates cognitive deficits in APP/PS1/tau triple transgenic mice by attenuating amyloid-beta, tau hyperphosphorylation and neurotrophic dysfunction. Ann Transl Med, 2020, 8(6): 328

[14] ZhaoLH, DingYX, ZhangL, et al.. Cornel iridoid glycoside improves memory ability and promotes neuronal survival in fmbria-fornix transected rats. Eur J Pharmacol, 2010, 647: 68-74

[15] YangCC, KuaiXX, LiYL, et al.. Cornel iridoid glycoside attenuates tau hyperphosphorylation by inhibition of PP2A demethylation. Evid Based Complement Alternat Med, 2013, 2013: 108486

[16] YangC, LiX, GaoW, et al.. Cornel Iridoid Glycoside Inhibits Tau Hyperphosphorylation via Regulating Cross-Talk Between GSK-3β and PP2A Signaling. Front Pharmacol, 2018, 9: 682

[17] ZhouY, ShiJ, ChuD, et al.. Relevance of Phosphorylation and Truncation of Tau to the Etiopathogenesis of Alzheimer’s Disease. Front Aging Neurosci, 2018, 10: 27

[18] VogelsT, MurgociAN, HromadkaT. Intersection of pathological tau and microglia at the synapse. Acta Neuropathol Commun, 2019, 7(1): 109

[19] ErcanE, EidS, WeberC, et al.. A validated antibody panel for the characterization of tau post-translational modifications. Mol Neurodegener, 2017, 12(1): 87

[20] NgPY, ChangIS, KohRY, et al.. Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development. Metab Brain Dis, 2020, 35(7): 1049-1066

[21] Guzmán-MartinezL, FaríasGA, MaccioniRB. Tau oligomers as potential targets for Alzheimer’s diagnosis and novel drugs. Front Neurol, 2013, 4(10): 167

[22] LiuF, IqbalK, Grundke-IqbalI, et al.. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett, 2002, 530(1–3): 209-214

[23] SokolowS, HenkinsKM, BilousovaT, et al.. Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer’s disease. J Neurochem, 2015, 133(3): 368-379

[24] MeyerV, DinkelPD, LuoY, et al.. Single mutations in tau modulate the populations of fibril conformers through seed selection. Angew Chem Int Ed Engl, 2014, 53(6): 1590-1593

[25] SoedaY, SaitoM, MaedaS, et al.. Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer’s Disease. J Alzheimers Dis, 2019, 68(4): 1-10

[26] Pampuscenko K, Morkuniene R, Krasauskas L, et al. Distinct Neurotoxic Effects of Extracellular Tau Species in Primary Neuronal-Glial Cultures. Mol Neurobiol, 2020. DOI: https://doi.org/10.1007/s12035-020-02150-7. Online ahead of print.

[27] MasliahE, MalloryM, AlfordM, et al.. Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease. Neurology, 2001, 56: 127-129

[28] YangX, YangY, LiuJ, et al.. Increased phosphorylation of tau and synaptic protein loss in the aged transgenic mice expressing familiar Alzheimer’s disease-linked presenilin 1 mutation. Neurochem Res, 2012, 37(1): 15-22

[29] KhakpaiF, NasehiM, ZarrindastMR. The role of NMDA receptors of the medial septum and dorsal hippocampus on memory acquisition. Pharmacol Biochem Behav, 2016, 143: 18-25

[30] DuY, FuM, HuangZ, et al.. TRPV1 activation alleviates cognitive and synaptic plasticity impairments through inhibiting AMPAR endocytosis in APP23/PS45 mouse model of Alzheimer’s disease. Aging Cell, 2020, 193: 13113